Sobi appoints Mats-Olof Wallin as interim Chief Financial Officer
Mats-Olof Wallin has been appointed interim Chief Financial Officer at Swedish
Orphan Biovitrum AB (Sobi). Wallin - until recently the CFO of Swedish biotech
company Biotage AB (publ.) - brings more than 30 years of experience in the
pharmaceutical industry, gained from various executive positions within
companies such as Pharmacia, Ortivus and Biotage. Wallin has been working at
Sobi for the past several months.
"We are glad to welcome Mats-Olof as interim CFO. Mats-Olof brings significant
experience to the role and will join our senior team in building a sustainable
company which brings value to all stakeholders", said CEO Geoffrey McDonough.
Annika Muskantor, who has been interim CFO since August 2012, will support Mats-
Olof in his new role during a transition period.
Continued McDonough: "I would like to thank Annika for her excellent work the
past year. She has built a strong financial platform which will continue to
support the development of this company."
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 480 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information - not for
Media relations Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
T: +46 70 410 71 80 T: +46 8 697 20 00